These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 11991676)

  • 21. Nanoparticles for delivery of chemotherapeutic agents to tumors.
    Vijayaraghavalu S; Raghavan D; Labhasetwar V
    Curr Opin Investig Drugs; 2007 Jun; 8(6):477-84. PubMed ID: 17621878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Introduction to resistance to anticancer agents.
    Kruh GD
    Oncogene; 2003 Oct; 22(47):7262-4. PubMed ID: 14576836
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical setbacks for toll-like receptor 9 agonists in cancer.
    Schmidt C
    Nat Biotechnol; 2007 Aug; 25(8):825-6. PubMed ID: 17687345
    [No Abstract]   [Full Text] [Related]  

  • 24. Targeted therapies: a nursing perspective.
    Kay P
    Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):1-4. PubMed ID: 16616280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nanoparticle and targeted systems for cancer therapy.
    Brannon-Peppas L; Blanchette JO
    Adv Drug Deliv Rev; 2004 Sep; 56(11):1649-59. PubMed ID: 15350294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST.
    Ratain MJ; Eckhardt SG
    J Clin Oncol; 2004 Nov; 22(22):4442-5. PubMed ID: 15483011
    [No Abstract]   [Full Text] [Related]  

  • 27. Drug delivery to tumours: recent strategies.
    Reddy LH
    J Pharm Pharmacol; 2005 Oct; 57(10):1231-42. PubMed ID: 16259751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical relevance of P-glycoprotein with respect to the application of resistance modifiers.
    Scheulen ME
    Int J Clin Pharmacol Ther; 1998 Jan; 36(1):41-5. PubMed ID: 9476147
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical drug trials.
    Edgar L
    Can Nurse; 1983 Feb; 79(2):24-5. PubMed ID: 6549907
    [No Abstract]   [Full Text] [Related]  

  • 30. Autophagy signaling in cancer and its potential as novel target to improve anticancer therapy.
    Moretti L; Yang ES; Kim KW; Lu B
    Drug Resist Updat; 2007; 10(4-5):135-43. PubMed ID: 17627865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The epothilones: how pharmacology relates to clinical utility.
    Michaud LB
    Ann Pharmacother; 2009 Jul; 43(7):1294-309. PubMed ID: 19584389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted therapies in lung cancer: a tribute to advancements in clinical research.
    McGee L
    ONS Connect; 2007; 22(8 Suppl):27-8. PubMed ID: 17824552
    [No Abstract]   [Full Text] [Related]  

  • 33. Resisting resistance.
    Ewan S
    Drug Discov Today; 2005 Aug; 10(15):1015. PubMed ID: 16055015
    [No Abstract]   [Full Text] [Related]  

  • 34. CDK inhibitors in cancer therapy: what is next?
    Malumbres M; Pevarello P; Barbacid M; Bischoff JR
    Trends Pharmacol Sci; 2008 Jan; 29(1):16-21. PubMed ID: 18054800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Taking stock of targeted therapy in cancer: rational expectations or irrational exuberance?
    Edelman MJ
    Expert Rev Anticancer Ther; 2003 Apr; 3(2):127-9. PubMed ID: 12722869
    [No Abstract]   [Full Text] [Related]  

  • 36. Radiation sensitizers: a selective review of molecules targeting DNA and non-DNA targets.
    Kvols LK
    J Nucl Med; 2005 Jan; 46 Suppl 1():187S-90S. PubMed ID: 15653668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
    Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
    Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A target or a demi-target.
    Mok TS
    Clin Lung Cancer; 2010 May; 11(3):147-8. PubMed ID: 20439189
    [No Abstract]   [Full Text] [Related]  

  • 39. Drug resistance in hematologic malignancies.
    Dalton W
    Clin Adv Hematol Oncol; 2005 Apr; 3(4):267-8. PubMed ID: 16166998
    [No Abstract]   [Full Text] [Related]  

  • 40. How can we improve clinical trials?
    Kaplan RS
    Nat Clin Pract Oncol; 2007 Apr; 4(4):206-7. PubMed ID: 17392712
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.